These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27885694)

  • 21. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
    de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
    J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence and pharmacokinetic study of two different omeprazole capsule formulations in healthy Bangladeshi volunteers.
    Joti JJ; Nahar K; Hasan A; Azad MA; Ullah MA; Islam SM; Hasnat A
    Arzneimittelforschung; 2009; 59(4):171-5. PubMed ID: 19517893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis.
    Wo JM; Eversmann J; Mann S
    Aliment Pharmacol Ther; 2010 Feb; 31(4):516-22. PubMed ID: 19925497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher AUCs on oral administration of omeprazole and felodipine in Indian volunteers--are they clinically important?
    Joseph T; Gowrishankar R
    Indian J Physiol Pharmacol; 1996 Jul; 40(3):253-6. PubMed ID: 8950143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of short-term light to heavy exercise on gastric ulcer development in horses and efficacy of omeprazole paste in preventing gastric ulceration.
    White G; McClure SR; Sifferman R; Holste JE; Fleishman C; Murray MJ; Cramer LG
    J Am Vet Med Assoc; 2007 Jun; 230(11):1680-2. PubMed ID: 17542738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers.
    Hussein RF; Lockyer M; Hammami MM
    Arzneimittelforschung; 2007; 57(2):101-5. PubMed ID: 17396620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule.
    Schaltenbrand R; Huber R; Cotoraci CA; Mascher H; Potthast H; Hole U
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):453-9. PubMed ID: 11680670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
    Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re-evaluation of the regulation of omeprazole in racehorses: An evidence-based approach.
    Viljanto M; Hillyer L; Hincks P; Pearce C; Paine SW
    J Vet Pharmacol Ther; 2018 Jun; 41(3):469-475. PubMed ID: 29468684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of omeprazole paste in foals and mature horses.
    Plue RE; Wall HG; Daurio C; Attebery DK; Cox JL; Wallace DH
    Equine Vet J Suppl; 1999 Apr; (29):63-6. PubMed ID: 10696297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of immobilization stress on the pharmacokinetics of omeprazole in rats.
    Watanabe K; Matsuka N; Okazaki M; Hashimoto Y; Araki H; Gomita Y
    Acta Med Okayama; 2002 Feb; 56(1):19-23. PubMed ID: 11873940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
    Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
    Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omeprazole--a new formulation.
    Armstrong D
    Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.
    Niioka T; Uno T; Sugimoto K; Sugawara K; Hayakari M; Tateishi T
    Eur J Clin Pharmacol; 2007 Nov; 63(11):1031-8. PubMed ID: 17701405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Omeprazol and ezomeprazol pharmacokinetics, duration of antisecretory effect, and reasons for their probable changes in duodenal ulcer].
    Serebrova SIu; Starodubtsev AK; Pisarev VV; Kondratenko SN; Vasilenko GF; Dobrovol'skiĭ OV
    Eksp Klin Gastroenterol; 2009; (4):86-92. PubMed ID: 19960999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.